Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00726739 · ClinicalTrials.gov registry record · Phase 2
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT00726739 is a Phase 2 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 21 participants.
The verdict
NCT00726739, a Phase 2 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
RATIONALE: Aldesleukin may stimulate the white blood cells to kill tumor cells. Vaccines may help the body build an effective immune response to kill tumor cells. Giving aldesleukin together with vaccine therapy may kill more tumor cells. It is not yet known whether aldesleukin is more effective with or without vaccine therapy in treating melanoma. PURPOSE: This randomized phase II trial is studying how well aldesleukin works when given with or without vaccine therapy in treating patients with stage IV melanoma.
Interventions
- BIOLOGICAL aldesleukin
- BIOLOGICAL allogeneic large multivalent immunogen vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2008-06 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00726739
The ClinicalTrials.gov registry entry for NCT00726739 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which aldesleukin is the first listed.
NCT00726739 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00726739 about?
NCT00726739 is a clinical study titled "Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma". RATIONALE: Aldesleukin may stimulate the white blood cells to kill tumor cells. Vaccines may help the body build an effective immune response to kill tumor cells. Giving aldesleukin together with vaccine therapy may kill more tumor cells. It is not yet known whether aldesleukin is more effective wit...
What is the current status of trial NCT00726739?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2008-06. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00726739?
The interventions under investigation include: aldesleukin (BIOLOGICAL), allogeneic large multivalent immunogen vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00726739?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.